Description: Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Home Page: www.novacyt.com
13 Avenue Morane Saulnier
Vélizy-Villacoublay,
78140
France
Phone:
33 1 39 46 51 04
Officers
| Name | Title |
|---|---|
| Mr. James Martin McCarthy | CFO, Acting CEO, Company Sec. & Director |
| Bryan Close | Chief Operations Officer |
| Ms. Wendy Karban | Group HR Mang. |
| Mr. David Franks | Chief HR Officer |
| Paul Oladimeji | Group Head of R&D |
| Mr. Gérald Ulrich | Chief Exec. Officer of Bus. Devel. |
| Mr. Steve Gibson | Group Financial Controller |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4268 |
| Price-to-Sales TTM: | 1.0197 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 210 |